

## Viracta Therapeutics to Present at Upcoming Investor Conferences in September

SAN DIEGO, Sept. 7, 2021 /PRNewswire/ -- [Viracta](#) Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management will present and be available for virtual one-on-one meetings at the H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference, September 13 – 15, 2021, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, September 20 – 23, 2021, and the 2021 Cantor Virtual Global Healthcare Conference, September 27 – 30, 2021.

Details on the presentations can be found below.

### **H.C. Wainwright 23rd Annual Global Investment Conference**

Presentation Date: Corporate presentation will be available on-demand to conference registrants starting at 7:00 AM ET on September 13, 2021

### **Oppenheimer Fall Healthcare Life Sciences & MedTech Summit**

Presentation Date: September 21, 2021

Presentation Time: 4:35 PM ET

Format: Corporate presentation

Webcast Link: <https://wsw.com/webcast/oppenheimer16/virx/2836187>

### **2021 Cantor Virtual Global Healthcare Conference**

Presentation Date: September 30, 2021

Presentation Time: 8:40 AM ET

Format: Corporate presentation

A replay of the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit presentation will be available on the "Events and Webcasts" section of the Viracta website at <https://viracta.investorroom.com/events-and-webcasts>.

### **About Viracta Therapeutics, Inc.**

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma. Viracta is also pursuing application of its inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.

For additional information please visit [www.viracta.com](http://www.viracta.com).

#### **Investor Relations Contact:**

Joyce Allaire

LifeSci Advisors

[jallaire@lifesciadvisors.com](mailto:jallaire@lifesciadvisors.com)

(212) 915-2569

#### **Company Contact:**

Dan Chevallard

Chief Operating Officer and Chief Financial Officer

[dchevallard@viracta.com](mailto:dchevallard@viracta.com)

(858) 771-4193

SOURCE Viracta

---

<https://viracta.investorroom.com/2021-09-07-Viracta-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-September>